Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian ...

Texas cities, counties, transit systems and special-purpose taxing districts will receive $1.2 billion in sales tax ...

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

It’s no surprise that waterjets are great for shallow-draft, highly maneuverable craft, but vessel designers are busting out ...

A contemporary review published in the American Journal of Hematology provides updated recommendations for allogeneic ...

A Freedom Front Plus councillor delivered a stern address to the Tshwane City Council on May 28, raising significant concerns over the financial instability of Housing Company Tshwane (HCT) ...

Georgia state legislators pulled the plug on EV tax credits a decade ago and now Congress is considering doing the same by cutting provisions in the Inflation Reduction Act.

The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

Saint-Louis, France and Dublin, Ireland - 3rd June 2025- Priothera Ltd., a late-stage biopharma company pioneering the ...

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...